Bisphosphonates in patients with renal cell carcinoma and bone metastases: a sunitinib global expanded-access trial subanalysis

Tonini G
Vincenzi B
Santini D

January 2011

Bone metastases have a major impact on morbidity and on mortality in cancer patients. Despite its cl...

Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid

Matti Aapro
Fred Saad

April 2012

Many patients with advanced genitourinary malignancies develop bone metastases, which can lead to po...

Zoledronic acid in the management of metastatic bone disease

Santini D
Fratto ME
Vincenzi B
Galluzzo S
Tonini G

January 2006

Bisphosphonate therapy has become a standard of therapy for patients with malignant bone disease. Mo...

Bisphosphonates in patients with renal cell carcinoma and bone metastases: a sunitinib global expanded-access trial subanalysis

Vrdoljak, Eduard
Gore, Martin
Leyman, Sophie
Szczylik, Cezary
Kharkevich, Galina
Schöffski, Patrick
Torday, Laszlo
Mardiak, Josef
Zhang, Ke
Sajben, Peter
Sella, Avishay

October 2015

ABSTRACT Aim: To investigate retrospectively the effects of bone metastases and bisphosphonates in ...

Fuhrman grade and concomitant bisphosphonates as additional prognostic factors in metastatic renal cell carcinoma with bone metastases treated with sunitinib

Beuselinck, Benoit
Medioni, J
Wolter, Pascal
Blesius, A
Karadimou, A
Schöffski, Patrick
Escudier, B J
Zucman-Rossi, J
Paridaens, Robert
Oudard, S

March 2011

388 Background: With a median progression-free survival(PFS) of 8.2 months (mo) (vs. 19.1 mo; p<0.00...

Renal cell carcinoma bone metastases: clinical advances

Chakshu Sahi
Jennifer J. Knox
Mark Clemons
Anthony M. Joshua
Reuben Broom

March 2010

Bone is a common site of metastatic spread in patients with advanced renal cell carcinoma (RCC) occu...

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.

Beuselinck, B
Wolter, P
Karadimou, A
Elaidi, R
Dumez, Herlinde
Rogiers, Annick
Van Cann, T
Willems, L
Body, Jean-Jacques
Berkers, J
Van Poppel, H
Lerut, E
Debruyne, P
Paridaens, R
Schöffski, P

November 2012

The presence of bone metastases in patients with metastatic renal cell carcinoma treated with oral t...

Efficacy of zoledronic acid in the treatment of bone metastases secondary to renal cell carcinoma

Schulman, Claude

November 2004

This subset analysis examined the therapeutic effect of zoledronic acid on patients with renal cell ...

Bisphosphonates: From preclinical evidence to survival data in the oncologic setting

Santini D
Galluzzo S
Fratto ME
Vincenzi B
Angeletti S
Dicuonzo G
Schiavon G
Tonini G.

January 2007

Bisphosphonate therapy has become a standard of therapy for patients with malignant bone disease. In...

Bisphosphonates: from preclinical evidence to survival data in the oncologic setting

Daniele Santini
Maria Elisabetta Fratto
Bruno Vincenzi
Silvia Angeletti
Giordano Dicuonzo
Gaia Schiavon
Giuseppe Tonini

December 2011

Bisphosphonate therapy has become a standard of therapy for patients with malignant bone disease. In...

Current approaches to bone-targeted therapy in genitourinary malignancies

Mulders, P.F.A.

January 2012

Contains fulltext : 110754.pdf (publisher's version ) (Open Access)Bone metastases...

Bone-Targeted Therapies for Elderly Patients with Renal Cell Carcinoma: Current and Future Directions

Roza, Thomas
Hakim, Lukman
Van Poppel, Hendrik
Joniau, Steven

November 2013

Bone metastases are very common in advanced renal cell carcinoma (RCC) and can have a huge impact on...

Denosumab: Second Chapter in Controlling Bone Metastases or a New Book?

October 2016

Boney involvement develops in approximately 73 % of patients with metastatic breast carcinoma, 68 % ...

Bisphosphonates Treatment in Metastatic Prostate Cancer

F. Berardinelli
M. Iannucci
V. Verratti
W. Fusco
M. Nicolai
R.L. Tenaglia

May 2005

The skeleton is the third most common site for cancer to spread after the liver and lungs. Malignanc...

Burden of metastatic bone disease from genitourinary malignancies.

Mulders, P.F.A.
Abrahamsson, P.A.
Bukowski, R.M.

January 2010

Item does not contain fulltextBone metastases are common among patients with stage IV genitourinary ...

Bisphosphonate anticancer activity

Tonini G
Vincenzi B
Santini D

January 2011

Bone metastases have a major impact on morbidity and on mortality in cancer patients. Despite its cl...

Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid

Matti Aapro
Fred Saad

April 2012

Many patients with advanced genitourinary malignancies develop bone metastases, which can lead to po...

Zoledronic acid in the management of metastatic bone disease

Santini D
Fratto ME
Vincenzi B
Galluzzo S
Tonini G

January 2006

Bisphosphonate therapy has become a standard of therapy for patients with malignant bone disease. Mo...

Bisphosphonates in patients with renal cell carcinoma and bone metastases: a sunitinib global expanded-access trial subanalysis

Vrdoljak, Eduard
Gore, Martin
Leyman, Sophie
Szczylik, Cezary
Kharkevich, Galina
Schöffski, Patrick
Torday, Laszlo
Mardiak, Josef
Zhang, Ke
Sajben, Peter
Sella, Avishay

October 2015

ABSTRACT Aim: To investigate retrospectively the effects of bone metastases and bisphosphonates in ...

Fuhrman grade and concomitant bisphosphonates as additional prognostic factors in metastatic renal cell carcinoma with bone metastases treated with sunitinib

Beuselinck, Benoit
Medioni, J
Wolter, Pascal
Blesius, A
Karadimou, A
Schöffski, Patrick
Escudier, B J
Zucman-Rossi, J
Paridaens, Robert
Oudard, S

March 2011

388 Background: With a median progression-free survival(PFS) of 8.2 months (mo) (vs. 19.1 mo; p<0.00...

Renal cell carcinoma bone metastases: clinical advances

Chakshu Sahi
Jennifer J. Knox
Mark Clemons
Anthony M. Joshua
Reuben Broom

March 2010

Bone is a common site of metastatic spread in patients with advanced renal cell carcinoma (RCC) occu...

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.

Beuselinck, B
Wolter, P
Karadimou, A
Elaidi, R
Dumez, Herlinde
Rogiers, Annick
Van Cann, T
Willems, L
Body, Jean-Jacques
Berkers, J
Van Poppel, H
Lerut, E
Debruyne, P
Paridaens, R
Schöffski, P

November 2012

The presence of bone metastases in patients with metastatic renal cell carcinoma treated with oral t...

Efficacy of zoledronic acid in the treatment of bone metastases secondary to renal cell carcinoma

Schulman, Claude

November 2004

This subset analysis examined the therapeutic effect of zoledronic acid on patients with renal cell ...

Bisphosphonates: From preclinical evidence to survival data in the oncologic setting

Santini D
Galluzzo S
Fratto ME
Vincenzi B
Angeletti S
Dicuonzo G
Schiavon G
Tonini G.

January 2007

Bisphosphonate therapy has become a standard of therapy for patients with malignant bone disease. In...

Bisphosphonates: from preclinical evidence to survival data in the oncologic setting

Daniele Santini
Maria Elisabetta Fratto
Bruno Vincenzi
Silvia Angeletti
Giordano Dicuonzo
Gaia Schiavon
Giuseppe Tonini

December 2011

Bisphosphonate therapy has become a standard of therapy for patients with malignant bone disease. In...

Current approaches to bone-targeted therapy in genitourinary malignancies

Mulders, P.F.A.

January 2012

Contains fulltext : 110754.pdf (publisher's version ) (Open Access)Bone metastases...

Bone-Targeted Therapies for Elderly Patients with Renal Cell Carcinoma: Current and Future Directions

Roza, Thomas
Hakim, Lukman
Van Poppel, Hendrik
Joniau, Steven

November 2013

Bone metastases are very common in advanced renal cell carcinoma (RCC) and can have a huge impact on...

Denosumab: Second Chapter in Controlling Bone Metastases or a New Book?

October 2016

Boney involvement develops in approximately 73 % of patients with metastatic breast carcinoma, 68 % ...

Bisphosphonates Treatment in Metastatic Prostate Cancer

F. Berardinelli
M. Iannucci
V. Verratti
W. Fusco
M. Nicolai
R.L. Tenaglia

May 2005

The skeleton is the third most common site for cancer to spread after the liver and lungs. Malignanc...

Burden of metastatic bone disease from genitourinary malignancies.

Mulders, P.F.A.
Abrahamsson, P.A.
Bukowski, R.M.

January 2010

Item does not contain fulltextBone metastases are common among patients with stage IV genitourinary ...

Bisphosphonate anticancer activity

Tonini G
Vincenzi B
Santini D

January 2011

Bone metastases have a major impact on morbidity and on mortality in cancer patients. Despite its cl...

Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid

Matti Aapro
Fred Saad

April 2012

Many patients with advanced genitourinary malignancies develop bone metastases, which can lead to po...

Zoledronic acid in the management of metastatic bone disease

Santini D
Fratto ME
Vincenzi B
Galluzzo S
Tonini G

January 2006

Bisphosphonate therapy has become a standard of therapy for patients with malignant bone disease. Mo...

Bisphosphonates in patients with renal cell carcinoma and bone metastases: a sunitinib global expanded-access trial subanalysis

Abstract

Extracted data

Bisphosphonates in patients with renal cell carcinoma and bone metastases: a sunitinib global expanded-access trial subanalysis

Abstract

Extracted data

Related items

Related items